News of Note—Sun Pharma slapped with Form 483; Catalent invests $14M; FDA draft guidance

iPhone
(Pixabay)

> Sun Pharmaceutical has been issued a Form 483 with 11 observations for its plant in Dadra, India. Story

> Somerset, New Jersey-based Catalent is investing $14 million to expand softgel capabilities at its facility in Eberbach, Germany, in response to demand for animal-free consumer health products. Release

> The FDA has issued new draft guidance for how companies should handle voluntary recalls. Release

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> East Rutherford, New Jersey-based CDMO Cambrex has opened a new 120-square-meter quality control laboratory at its site in Milan, Italy. Release

 

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.